References
- 1Thomas EA, Kadyan KR. Alopecia areata and autoimmunity: a clinical study. Indian J Dermatol. 2008; 53(2): 70–74. DOI: 10.4103/0019-5154.41650
- 2Marshall A, Williams MJ. Alopecia and levodopa. Br Med J. 1971; 2(5752): 47. DOI: 10.1136/bmj.2.5752.47
- 3Katz KA, Cotsarelis G, Gupta R, Seykora JT. Telogen effluvium associated with the dopamine agonist pramipexole in a 55-year-old woman with Parkinson’s disease. J Am Acad Dermatol. 2006; 55(5 SUPPL.): 103–104. DOI: 10.1016/j.jaad.2005.09.039
- 4Grauer MT, Sieb JP. Alopecia induced by dopamine agonists [4]. Neurology. 2002; 59(12): 2012. DOI: 10.1212/WNL.59.12.2012
- 5Miwa H, Kondo T. Hair loss induced by dopamine agonist: Case report and review of the literature. Park Relat Disord. 2003; 10(1): 51–52. DOI: 10.1016/S1353-8020(03)00058-0
- 6Langan EA, Lisztes E, Bíro T, et al. Dopamine is a novel, direct inducer of catagen in human scalp hair follicles in vitro. Br J Dermatol. 2013; 168(3): 520–525. DOI: 10.1111/bjd.12113
- 7Scribner MD. Propranolol Therapy. Arch Dermatol. 1977; 113(Sept): 1303. DOI: 10.1001/archderm.1977.01640090151053
- 8Fraunfelder FT, Meyer SM, Menacker SJ. Alopecia possibly secondary to topical ophthalmic beta-blockers. JAMA. 1990; 263(11): 1493–1494. DOI: 10.1001/jama.1990.03440110055020
- 9Pillans PJ, Woods DJ. Drug-associated alopecia. Int J Dermatol. 1995; 34(3): 149–158. DOI: 10.1111/j.1365-4362.1995.tb01556.x
- 10Mercke Y, Sheng H, Khan T, Lippmann S. Hair loss in psychopharmacology. Ann Clin Psychiatry. 2000; 12(1): 35–42. DOI: 10.1023/A:1009074926921